165 related articles for article (PubMed ID: 30387392)
1. Drug Design of Inhibitors of Alzheimer's Disease (AD): POM and DFT Analyses of Cholinesterase Inhibitory Activity of β-amino di-Carbonyl Derivatives.
Hadda TB; Rauf A; Zgou H; Senol FS; Orhan IE; Mabkhot YN; Althagafi II; Farghaly TA; Alterary S
Mini Rev Med Chem; 2019; 19(8):688-705. PubMed ID: 30387392
[TBL] [Abstract][Full Text] [Related]
2. Cholinesterase Inhibitory Activity of Some semi-Rigid Spiro Heterocycles: POM Analyses and Crystalline Structure of Pharmacophore Site.
Hadda TB; Talhi O; Silva ASM; Senol FS; Orhan IE; Rauf A; Mabkhot YN; Bachari K; Warad I; Farghaly TA; Althagafi II; Mubarak MS
Mini Rev Med Chem; 2018; 18(8):711-716. PubMed ID: 28714400
[TBL] [Abstract][Full Text] [Related]
3. Spiro Heterocyclic Compounds as Potential Anti-Alzheimer Agents (Part 2): Their Metal Chelation Capacity, POM Analyses and DFT Studies.
Hadda TB; Deniz FSS; Orhan IE; Zgou H; Rauf A; Mabkhot YN; Bennani B; Emam DR; Kheder NA; Asayari A; Muhsinah AB; Maalik A
Med Chem; 2021; 17(8):834-843. PubMed ID: 32520690
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of selective and potent Carbazole-based butyrylcholinesterase inhibitors.
Ghobadian R; Nadri H; Moradi A; Bukhari SNA; Mahdavi M; Asadi M; Akbarzadeh T; Khaleghzadeh-Ahangar H; Sharifzadeh M; Amini M
Bioorg Med Chem; 2018 Sep; 26(17):4952-4962. PubMed ID: 30190181
[TBL] [Abstract][Full Text] [Related]
5. Identification of New Chromenone Derivatives as Cholinesterase Inhibitors and Molecular Docking Studies.
Iqbal J; Abbasi MSA; Zaib S; Afridi S; Furtmann N; Bajorath J; Langer P
Med Chem; 2018; 14(8):809-817. PubMed ID: 29473519
[TBL] [Abstract][Full Text] [Related]
6. Cholinesterases inhibition and molecular modeling studies of piperidyl-thienyl and 2-pyrazoline derivatives of chalcones.
Shah MS; Khan SU; Ejaz SA; Afridi S; Rizvi SUF; Najam-Ul-Haq M; Iqbal J
Biochem Biophys Res Commun; 2017 Jan; 482(4):615-624. PubMed ID: 27865835
[TBL] [Abstract][Full Text] [Related]
7. Molecular modeling, docking and ADMET studies applied to the design of a novel hybrid for treatment of Alzheimer's disease.
da Silva CH; Campo VL; Carvalho I; Taft CA
J Mol Graph Model; 2006 Oct; 25(2):169-75. PubMed ID: 16413803
[TBL] [Abstract][Full Text] [Related]
8. Acetamide Derivatives of Chromen-2-ones as Potent Cholinesterase Inhibitors.
Prasad S; Kumar B; Kumar S; Chand K; Kamble SS; Gautam HK; Sharma SK
Arch Pharm (Weinheim); 2017 Aug; 350(8):. PubMed ID: 28699213
[TBL] [Abstract][Full Text] [Related]
9. Selective in vitro and in silico butyrylcholinesterase inhibitory activity of diterpenes and rosmarinic acid isolated from Perovskia atriplicifolia Benth. and Salvia glutinosa L.
Senol FS; Ślusarczyk S; Matkowski A; Pérez-Garrido A; Girón-Rodríguez F; Cerón-Carrasco JP; den-Haan H; Peña-García J; Pérez-Sánchez H; Domaradzki K; Orhan IE
Phytochemistry; 2017 Jan; 133():33-44. PubMed ID: 27817931
[TBL] [Abstract][Full Text] [Related]
10. Syntheses, cholinesterases inhibition, and molecular docking studies of pyrido[2,3-b]pyrazine derivatives.
Hameed A; Zehra ST; Shah SJ; Khan KM; Alharthy RD; Furtmann N; Bajorath J; Tahir MN; Iqbal J
Chem Biol Drug Des; 2015 Nov; 86(5):1115-20. PubMed ID: 25951978
[TBL] [Abstract][Full Text] [Related]
11. 9-Substituted acridine derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors possessing antioxidant activity for Alzheimer's disease treatment.
Makhaeva GF; Lushchekina SV; Boltneva NP; Serebryakova OG; Rudakova EV; Ustyugov AA; Bachurin SO; Shchepochkin AV; Chupakhin ON; Charushin VN; Richardson RJ
Bioorg Med Chem; 2017 Nov; 25(21):5981-5994. PubMed ID: 28986116
[TBL] [Abstract][Full Text] [Related]
12. In silico modeling of the specific inhibitory potential of thiophene-2,3-dihydro-1,5-benzothiazepine against BChE in the formation of beta-amyloid plaques associated with Alzheimer's disease.
Ul-Haq Z; Khan W; Kalsoom S; Ansari FL
Theor Biol Med Model; 2010 Jun; 7():22. PubMed ID: 20550720
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory activities of major anthraquinones and other constituents from Cassia obtusifolia against β-secretase and cholinesterases.
Jung HA; Ali MY; Jung HJ; Jeong HO; Chung HY; Choi JS
J Ethnopharmacol; 2016 Sep; 191():152-160. PubMed ID: 27321278
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of new 2-benzoxazolinone derivatives as potential cholinesterase inhibitors for therapy of alzheimer's disease.
Szymański P; Janik A; Zurek E; Mikiciuk-Olasik E
Pharmazie; 2011 Jun; 66(6):399-403. PubMed ID: 21699076
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Biological Evaluation of New Cholinesterase Inhibitors for Alzheimer's Disease.
Hussein W; Sağlık BN; Levent S; Korkut B; Ilgın S; Özkay Y; Kaplancıklı ZA
Molecules; 2018 Aug; 23(8):. PubMed ID: 30110946
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, biological evaluation and molecular modeling of new tetrahydroacridine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Bajda M; Jończyk J; Malawska B; Czarnecka K; Girek M; Olszewska P; Sikora J; Mikiciuk-Olasik E; Skibiński R; Gumieniczek A; Szymański P
Bioorg Med Chem; 2015 Sep; 23(17):5610-8. PubMed ID: 26242241
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, Characterization and Cholinesterase Inhibition Studies of New Arylidene Aminothiazolylethanone Derivatives.
Channar PA; Shah MS; Saeed A; Khan SU; Larik FA; Shabir G; Iqbal J
Med Chem; 2017; 13(7):648-653. PubMed ID: 28266279
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Novel Pyrazolopyrimidinone Derivatives as Phosphodiesterase 9A Inhibitors Capable of Inhibiting Butyrylcholinesterase for Treatment of Alzheimer's Disease.
Yu YF; Huang YD; Zhang C; Wu XN; Zhou Q; Wu D; Wu Y; Luo HB
ACS Chem Neurosci; 2017 Nov; 8(11):2522-2534. PubMed ID: 28783948
[TBL] [Abstract][Full Text] [Related]
19. Tetrahydroacridine derivatives with fluorobenzoic acid moiety as multifunctional agents for Alzheimer's disease treatment.
Czarnecka K; Szymański P; Girek M; Mikiciuk-Olasik E; Skibiński R; Kabziński J; Majsterek I; Malawska B; Jończyk J; Bajda M
Bioorg Chem; 2017 Jun; 72():315-322. PubMed ID: 28501648
[TBL] [Abstract][Full Text] [Related]
20. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
